Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
European Journal of Haematology|May 8, 2015
Molecular diagnostics of myeloproliferative neoplasmsStephen E Langabeer, Hajnalka Andrikovics, Julia Asp, et al.British Journal of Haematology|June 14, 2013
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemiaChristen L Andersen, Mary F McMullin, Elisabeth Ejerblad, et al.Plos Medicine|June 14, 2006
Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiologyThomas G Smith, Jerome T Brooks, George M Balanos, et al.Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.Future Oncology (London, England)|January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicSrdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 11, 2011
Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutationFederico Formenti, Philip A Beer, Quentin P P Croft, et al.Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Regulation of human metabolism by hypoxia-inducible factorFederico Formenti, Dumitru Constantin-Teodosiu, Yaso Emmanuel, et al.Pageof 4